Intercell announces initial results of Phase II clinical trial evaluating V710, an investigational Staphylococcus aureus vaccine
Primary Immunogenicity and Safety objectives met
22-Nov-2010 -
Intercell AG announced top-line results from a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. The study, conducted by Intercell's collaborator, a subsidiary of Merck & Co., Inc, was designed to evaluate the safety ...
antibodies
clinical trials
immunogenicity
+3